From: C-reactive protein for prediction of atrial fibrillation recurrence after catheter ablation
CRP Level | |||||
---|---|---|---|---|---|
Characteristic | Quartile 1 (N = 201) | Quartile 2 (N = 171) | Quartile 3 (N = 167) | Quartile 4 (N = 172) | P trend |
Age, years | 59.1 ± 10.7 | 60.1 ± 8.8 | 61.5 ± 8.8 | 61.6 ± 9.5 | 0.016 |
Female sex | 42 (21) | 36 (21) | 45 (27) | 50 (30) | 0.019 |
Body mass index, kg/m2 | 25.4 ± 3.9 | 27.4 ± 4.0 | 27.7 ± 4.3 | 29.2 ± 6.1 | < 0.001 |
Systolic blood pressure, mm Hg | 135 ± 17 | 135 ± 18 | 135 ± 18 | 136 ± 20 | 0.78 |
Type of atrial fibrillation | < 0.001 | ||||
Paroxysmal | 139 (70) | 108 (63) | 97 (58) | 90 (52) | |
Persistent | 61 (30) | 63 (37) | 69 (42) | 82 (48) | |
Atrial fibrillation duration, years | 2.3 (0.6–6.6) | 1.7 (0.5–4.8) | 2.2 (0.6–6.1) | 2.0 (0.6–5.6) | 0.72 |
Echocardiographic parameters | |||||
LAD, mm | 39 ± 7 | 42 ± 7 | 42 ± 7 | 43 ± 6 | < 0.001 |
LVEF, % | 58 ± 10 | 57 ± 9 | 57 ± 10 | 55 ± 12 | < 0.001 |
Laboratory data | |||||
WBC, mm3 | 5860 (5020–6840) | 6135 (5135–7515) | 6440 (5290–7820) | 6900 (5740–8400) | < 0.001 |
Serum creatinine, μmol/l | 84 (74–95) | 82 (74–93) | 83 (72–94) | 84 (73–97) | 0.94 |
Medical history | |||||
Coexistent atrial flutter | 36 (18) | 35 (20) | 30 (18) | 29 (17) | 0.68 |
Hypertension | 93 (47) | 84 (50) | 90 (54) | 117 (69) | < 0.001 |
Diabetes | 13 (7) | 10 (6) | 12 (7) | 20 (12) | 0.07 |
Stroke | 20 (10) | 9 (5) | 10 (6) | 15 (9) | 0.64 |
Heart failure | 11 (6) | 11 (7) | 16 (10) | 26 (15) | 0.001 |
Myocardial infarction | 9 (5) | 8 (5) | 8 (5) | 13 (8) | 0.23 |
History of amiodarone treatment | < 0.001 | ||||
Current | 30 (15) | 25 (15) | 29 (17) | 37 (22) | |
Previous use | 24 (12) | 29 (17) | 30 (18) | 40 (23) | |
Never use | 147 (73) | 117 (68) | 108 (65) | 95 (55) |